RxDoctor Payments Data

Jayne Koellhoffer, MD

Internal Medicine · Doylestown, PANPI 1508220765

Payments from drug & device makers

$2,002in general payments, 2019–2025

Across 106 payments — averaging $18.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$380
  • Novo Nordisk$348
  • Pfizer$242
  • Daiichi Sankyo Inc.$161
  • Lilly USA, LLC$158
  • GSK$94
  • plus $621 from 15 others

What the payments were for

  • Food & beverage$2,002100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,002 in reported general payments places this provider in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$88,177
Medicare patients
318
Services billed
1,372

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide93$107,301
JardianceEmpagliflozin83$71,240
EliquisApixaban59$54,116
XareltoRivaroxaban34$28,143
RybelsusSemaglutide24$25,803
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$6,644
MyrbetriqMirabegron14$6,047
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$5,785
Atorvastatin Calcium447$5,002
Arnuity ElliptaFluticasone Furoate18$4,594
Novolog FlexpenInsulin Aspart15$3,952
Duloxetine Hcl138$3,421
Levothyroxine Sodium248$3,397
SynthroidLevothyroxine Sodium50$3,253
Celecoxib16$2,408

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$348$133,104117 claims
PfizerEliquis$242$54,11659 claims
Johnson & JohnsonXarelto$28$28,14334 claims
Astellas Pharma US IncMyrbetriq$82$6,04714 claims
GSKArnuity Ellipta$94$4,59418 claims
AbbVieSynthroid$380$3,25350 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Doylestown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →